A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

Healthy Subjects Clinical Trial

Official title:

A Randomized, Open-label, 3-period Cross-over Study to Assess the Pharmacokinetics of Selatogrel (ACT-246475) in Healthy Subjects After Subcutaneous Administration by Syringe and Auto-injector

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04557280
• Other study ID #: ID-076-105
• Status: Completed
• Phase: Phase 1
• Start date: November 6, 2020
• Est. completion date: December 19, 2020

Study information

• Verified date: November 2022
• Source: Idorsia Pharmaceuticals Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose is to study the pharmacokinetics of selatogrel (ACT-246475) using different administration modes and formulations. The clinical pharmacology data will be used to support demonstration of bioequivalence and interchangeability of the different formulations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 19, 2020
• Est. primary completion date: December 19, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

• Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.
• Healthy male or female participant aged between 18 and 59 years (inclusive) at screening.
• Body mass index of 18.0 to 31.9 kg/m2 (inclusive) at screening and a minimum weight of 50.0 kg at screening and on Day -1.
• Systolic blood pressure 100 to 140 mmHg, diastolic blood pressure 50 to 90 mmHg, and pulse rate 45 to 100 bpm (inclusive), measured on the left arm, after 5 minutes in the supine position at screening and Day-1.
• 12-lead electrocardiogram (ECG) without clinically relevant abnormalities, measured after 5 min in the supine position at screening and on Day-1.
• Clinical laboratory values are within the standard normal ranges or determined to be clinically insignificant in the opinion of the investigator at screening and on Day -1.
• Women must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline (i.e., Day -1 of the first period). Women of childbearing potential must consistently and correctly use (from screening, during the entire study, and for at least 30 days after last study treatment injection) an acceptable effective method of contraception, be sexually inactive, or have a vasectomized partner. If a hormonal contraceptive is used, it must be initiated at least 1 month before first treatment administration.
• Women of non-childbearing potential.

Exclusion Criteria:

• Pregnant or lactating woman.
• Previous exposure to selatogrel (ACT-246475).
• Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs, P2Y12 receptor antagonists, or any medication with blood-thinning activity (i.e., injectable or oral anticoagulants) within 3 weeks prior to study treatment administration.
• Treatment with another investigational small molecule drug within 30 days or 5 x terminal half-lives ([t½], whichever is longer) or with an investigational biologic drug within 90 days prior to screening.
• Known hypersensitivity to P2Y12 receptor antagonists or to excipients used in any of the formulations.
• History or clinical evidence of alcoholism or drug abuse within 3 years prior to screening.
• History of major medical or surgical disorders, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
• Family or personal history of prolonged bleeding (e.g., after surgical intervention) or bleeding disorders (e.g., thrombocytopenia, clotting disturbances), intracranial vascular diseases, stroke, transient ischemic attack, reasonable suspicion of vascular malformations, peptic ulcers.
• Platelet count less than 120 x10^9 per litre at screening and on Day-1.
• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Combination Product:
• Selatogrel
A single subcutaneous injection of 16 mg.

Drug:
• Selatogrel
A single subcutaneous injection of 16 mg.

Locations

Country	Name	City	State
United States	Altasciences Clinical Kansas, Inc	Overland Park	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Idorsia Pharmaceuticals Ltd.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Zenklusen I, Hsin CH, Schilling U, Kankam M, Krause A, Ufer M, Dingemanse J. Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y(12) Receptor Antagonist Selatogrel in Healthy Subjects. Clin Pharmacoki — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration-time curve (AUC0-t) of selatogrel		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.
Primary	The area under the plasma concentration-time curve from zero to infinity (AUC0-inf) of selatogrel		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.
Primary	The maximum plasma concentration (Cmax) of selatogrel		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.
Primary	Time to reach Cmax (tmax)		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.
Primary	Terminal half-life (t½) of selatogrel		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.
Secondary	Change from baseline in systolic and diastolic supine blood pressure		Multiple predefined times on Day 1 (pre-dose) up to Day 3.
Secondary	Change from baseline in pulse rate		Multiple predefined times on Day 1 (pre-dose) up to Day 3.
Secondary	Change from baseline in body weight		Multiple predefined times on Day 1 (pre-dose) up to Day 3.
Secondary	Change from baseline in the electric activity of the heart (12-lead electrocardiogram)	Changes in the PQ-, PR-, RR-, and QRS-interval will be measured. In addition, the QTc-interval corrected for heart rate using Bazett's (QTcB) and Fridericia's formula (QTcF) will be assessed.	Multiple predefined times on Day 1 (pre-dose) up to Day 3.
Secondary	Change from baseline in coagulation laboratory tests	Blood samples will be taken under fasted conditions and the following tested: prothrombin time and international normalized ratio, as well as activated partial thromboplastin time.	Multiple predefined times on Day 1 (pre-dose) up to Day 3.
Secondary	Change from baseline in clinical chemistry tests	Blood samples will be taken under fasted conditions and the following tested: aspartate aminotransferase / alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, total and direct bilirubin, lactate dehydrogenase; creatinine, urea; urate; glucose; cholesterol, triglycerides; sodium, potassium, chloride, calcium; protein, albumin.	Multiple predefined times on Day 1 (pre-dose) up to Day 3.
Secondary	Change from baseline in clinical hematology tests	Blood samples will be taken under fasted conditions and the following tested: hemoglobin, hematocrit, erythrocytes, leukocytes; as well as a differential blood count (including basophils, eosinophils, neutrophils, lymphocytes and monocytes); and platelets.	Multiple predefined times on Day 1 (pre-dose) up to Day 3.